Evolocumab 140 mg/mL Subcutaneous Injection 1 milliliter (mL) pre-filled injector Pen x 3 for a monthly dose of 420 mg for 6 months.
ApprovedUNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Peripheral Arterial Disease
Conditions
Peripheral Arterial Disease
Trial Timeline
Dec 14, 2017 → Mar 30, 2021
NCT ID
NCT04306081About Evolocumab 140 mg/mL Subcutaneous Injection 1 milliliter (mL) pre-filled injector Pen x 3 for a monthly dose of 420 mg for 6 months.
Evolocumab 140 mg/mL Subcutaneous Injection 1 milliliter (mL) pre-filled injector Pen x 3 for a monthly dose of 420 mg for 6 months. is a approved stage product being developed by Amgen for Peripheral Arterial Disease. The current trial status is unknown. This product is registered under clinical trial identifier NCT04306081. Target conditions include Peripheral Arterial Disease.
What happened to similar drugs?
8 of 20 similar drugs in Peripheral Arterial Disease were approved
Approved (8) Terminated (2) Active (11)
Hype Score Breakdown
Clinical
20
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04306081 | Approved | UNKNOWN |
Competing Products
20 competing products in Peripheral Arterial Disease